Phase 1 dose-escalation study of E7820, a novel anti-angiogenic agent, administered orally twice-daily to patients with advanced, refractory solid tumors

被引：0
|
作者：
Kristeleit, R. [1 ]
Plummer, R. [2 ]
Ranson, M. [3 ]
Slater, S. [4 ]
Witteveen, P. O. [5 ]
Reyderman, L. [6 ]
De las Heras, B. [7 ]
Verbel, D. [8 ]
Ink, B. [7 ]
Schellens, J. H. M. [9 ]
机构：
[1] UCL Canc Inst, London, England
[2] Sir Bobby Robson Canc Trials Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[3] Christies NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[4] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[5] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[6] Eisai Inc, Clin Pharmacol & Translat Med, Woodcliff Lake, NJ USA
[7] Eisai Ltd, Oncol, Hatfield, Herts, England
[8] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[9] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
812
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors.
    Mita, M. M.
    Mita, A. C.
    Ricart, A.
    Rodon, J.
    Till, E.
    Okereke, C.
    Desai, P.
    Zang, E.
    Rowinsky, E. K.
    Takimoto, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 132S - 132S
  • [2] A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
    Saif, Muhammad Wasif
    Takimoto, Chris
    Mita, Monica
    Banerji, Udai
    Lamanna, Nicole
    Castro, Januario
    O'Brien, Susan
    Stogard, Christopher
    Von Hoff, Daniel
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 445 - 455
  • [3] Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors
    Yamada, K.
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, Y.
    Suzuki, S.
    Kobayashi, N.
    Koizumi, F.
    Nishio, K.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors
    Doi, T.
    Ohtsu, A.
    Nakagawa, K.
    Okamoto, I.
    Kurei, K.
    Kobayashi, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 114 - 114
  • [5] A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors
    El-Khoueiry, A. B.
    Iqbal, S.
    Feit, K.
    Lenz, H. J.
    Okereke, C.
    Krivelevich, I.
    Goldberg, T.
    Conti, P.
    Rossignol, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
    B. Milojkovic Kerklaan
    S. Slater
    M. Flynn
    A. Greystoke
    P. O. Witteveen
    M. Megui-Roelvink
    F. de Vos
    E. Dean
    L. Reyderman
    L. Ottesen
    M. Ranson
    M. P. J. Lolkema
    R. Plummer
    R. Kristeleit
    T. R. J. Evans
    J. H. M. Schellens
    Investigational New Drugs, 2016, 34 : 329 - 337
  • [7] A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
    Kerklaan, B. Milojkovic
    Slater, S.
    Flynn, M.
    Greystoke, A.
    Witteveen, P. O.
    Megui-Roelvink, M.
    de Vos, F.
    Dean, E.
    Reyderman, L.
    Ottesen, L.
    Ranson, M.
    Lolkema, M. P. J.
    Plummer, R.
    Kristeleit, R.
    Evans, T. R. J.
    Schellens, J. H. M.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 329 - 337
  • [8] A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors
    Onozawa, Y.
    Boku, N.
    Fukutomi, A.
    Ohtsu, A.
    Doi, T.
    Yoshino, T.
    Koizumi, W.
    Tanabe, S.
    Sasaki, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 134 - 135
  • [9] A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors
    Rosen, L. S.
    Galatin, P.
    Fehling, J. M.
    Laux, I.
    Dinolfo, M.
    Frye, J.
    Laird, D.
    Sikic, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
    Camacho, Luis H.
    Olson, Jon
    Tong, William P.
    Young, Charles W.
    Spriggs, David R.
    Malkin, Mark G.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (02) : 131 - 138
12345